NCT04828486View on ClinicalTrials.gov

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

September 18, 2024

Study Completion Date

August 31, 2025

Conditions
Advanced Hepatocellular CarcinomaBCLC Stage A Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma
Interventions
DRUG

Futibatinib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04828486 - Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer | Biotech Hunter | Biotech Hunter